Sandoz Family to Sell $2.9 Billion Stake in Novartis
(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.
FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate
FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid ...
Sandoz family to get $2.9 billion from offloading part of its Novartis stake
The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a ...
Syngenta acquires genetic repository from Novartis to boost biologic crop protection
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...
Multiple Sclerosis News Today17h
Delays of MS diagnosis in Finland reduced by half over last decade
Since 2013, diagnoses of multiple sclerosis (MS) in Finland take less time after symptom onset and treatments follow the ...
Novartis holder Emasan selling 26.5M shares, Bloomberg reports
Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...
Sandoz Family Pares Novartis Stake With $2.9 Billion Sale
Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...